Each combination Combunox™ (oxycodone hcl and ibuprofen) tablet contains: Oxycodone HCl, USP 5 mg
Ibuprofen, USP 400 mg Combunox (oxycodone hcl and ibuprofen) is supplied in a fixed combination tablet form for oral administration and combines the opioid analgesic agent, oxycodone HCl, with the nonsteroidal anti-inflammatory (NSAID) agent, ibuprofen. Oxycodone HCl is a centrally acting semisynthetic opioid analgesic. Its chemical name is 4,5α-Epoxy-14-hydroxy-3-methoxy-methylmorphinan-6-one hydrochloride. Its chemical formula is C18H21NO4 HCl and molecular weight is 351.83. Its structural formula is: Ibuprofen is a nonsteroidal anti-inflammatory drug with analgesic and antipyretic properties. Its chemical name is (±)-2-(p-isobutylphenyl) propionic acid. Its chemical formula is C13H18O2 and molecular weight is 206.29. Its structural formula is: Inactive ingredients in Combunox (oxycodone hcl and ibuprofen) tablets include: sodium starch glycolate, microcrystalline cellulose, colloidal silicon dioxide, stearic acid, calcium stearate, carboxymethylcellulose, povidone, Opadry® II White, Y-22 7719 coloring agent. Opadry® II White, Y-22 7719 coloring agent consists of titanium dioxide, polydextrose, hypromellose, triacetin and polyethylene glycol 8000.

Source: http://www.rxlist.com

Listed below are the adverse event incidence rates from single dose analgesia trials in which a total of 2437 patients received either Combunox (oxycodone hcl and ibuprofen) , ibuprofen (400 mg), oxycodone HCl (5 mg), or placebo. Adverse event information is also provided from an additional 334 patients who were exposed to Combunox (oxycodone hcl and ibuprofen) in a multiple dose analgesia trial, without placebo or active component comparison arms, given up to four times daily for up to 7 days. Adverse Events Which Occurred at a Frequency of ≥ 1% and at a Higher Incidence than in the Placebo Group in Single Dose Studies
  5/400 mg
(n=923) 400mg
Ibuprofen
(n=913) 5mg
Oxycodone
HCl (n = 286) Placebo
(n=315) Digestive   Nausea 81 (8.8%) 44 (4.8%) 46 (16.1%) 21 (6.7%)   Vomiting 49 (5.3%) 16 (1.8%) 30 (10.5%) 10 (3.2%)   Flatulence 9 (1.0%) 7 (0.8%) 3 (1.0%) 0 Nervous System   Somnolence 67 (7.3%) 38 (4.2%) 12 (4.2%) 7 (2.2%)   Dizziness 47 (5.1%) 21 (2.3%) 17 (5.9%) 8 (2.5%) Skin and Appendages   Sweat 15 (1.6%) 7 (0.8%) 4 (1.4%) 1 (0.3%) Adverse events that were reported by at least 1% of patients taking Combunox (oxycodone hcl and ibuprofen) but were observed at a greater incidence in the placebo treated patients were fever, headache and pruritus. Adverse events that occurred in less than 1% and in at least two Combunox (oxycodone hcl and ibuprofen) treated patients in Single Dose studies not listed above include the following: Body as Whole: abdominal pain, asthenia, chest pain, enlarged abdomen. Cardiovascular System: hypotension, syncope, tachycardia, vasodilation. Digestive System: constipation, dry mouth, dyspepsia, eructation, ileus. Hemic and Lymphatic System: anemia. Metabolic and Nutritional Disorders: edema. Nervous System: euphoria, insomnia, nervousness. Respiratory System: hypoxia, lung disorder, pharyngitis. Urogenital System: urinary retention. Adverse events that occurred in the Multiple Dose study in at least 2% of patients treated with Combunox (oxycodone hcl and ibuprofen) include the following: Body as Whole: asthenia (3.3%), fever (3.0%), headache (10.2%). Cardiovascular System: vasodilation (3.0%). Digestive System: constipation (4.5%), diarrhea (2.1%), dyspepsia (2.1%), nausea (25.4%), vomiting (4.5%). Nervous System: dizziness (19.2%), somnolence (17.4%). Adverse events that occurred in less than 2% of and at least two Combunox (oxycodone hcl and ibuprofen) treated patients in the Multiple Dose study not listed previously include the following: Body as Whole: back pain, chills, infection. Cardiovascular System: thrombophlebitis. Hemic and Lymphatic System: ecchymosis. Metabolic and Nutritional Disorders: hypokalemia. Musculoskeletal System: arthritis. Nervous System: abnormal thinking, anxiety, hyperkinesia, hypertonia. Skin and Appendages: rash. Special Senses: amblyopia, taste perversion. Urogenital System: urinary frequency. Drug Abuse And Dependence Combunox (oxycodone hcl and ibuprofen) contains oxycodone, which is a mu-opioid agonist with an abuse liability similar to other opioid agonists and is a Schedule II controlled substance. Combunox (oxycodone hcl and ibuprofen) , and other opioids used in analgesia, can be abused and are subject to criminal diversion. Addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. Drug addiction is a treatable disease utilizing a multidisciplinary approach, but relapse is common. “Drug seeking” behavior is very common in addicts and drug abusers. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated “loss” of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating physician(s). “Doctor shopping” to obtain additional prescriptions is common among drug abusers and people suffering from untreated addiction. Abuse and addiction are separate and distinct from physical dependence and tolerance. Physical dependence usually assumes clinically significant dimensions only after several weeks of continued opioid use, although a mild degree of physical dependence may develop after a few days of opioid therapy. Tolerance, in which increasingly large doses are required in order to produce the same degree of analgesia, is manifested initially by a shortened duration of analgesic effect, and subsequently by decreases in the intensity of analgesia. The rate of development of tolerance varies among patients. Physicians should be aware that abuse of opioids can occur in the absence of true addiction and is characterized by misuse for non-medical purposes, often in combination with other psychoactive substances. Combunox (oxycodone hcl and ibuprofen) , like other opioids, may be diverted for non-medical use. Record-keeping of prescribing information, including quantity, frequency, and renewal requests is strongly advised. Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs. Read the Combunox (oxycodone hcl and ibuprofen) Side Effects Center for a complete guide to possible side effectsLearn More »

Source: http://www.rxlist.com

Carefully consider the potential benefits and risks of Combunox (oxycodone hcl and ibuprofen) and other treatment options before deciding to use Combunox (oxycodone hcl and ibuprofen) . Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS). After observing the response to initial therapy with Combunox (oxycodone hcl and ibuprofen) , the dose and frequency should be adjusted to suit an individual patient's needs.” For the management of acute moderate to severe pain, the recommended dose of Combunox (oxycodone hcl and ibuprofen) is one tablet given orally. Dosage should not exceed 4 tablets in a 24-hour period and should not exceed 7 days.

Source: http://www.rxlist.com

Oxycodone is metabolized in part to oxymorphone via the cytochrome P450 isoenzyme CYP2D6. While this pathway may be blocked by a variety of drugs (e.g., certain cardiovascular drugs and antidepressants), such blockade has not yet been shown to be of clinical significance with this agent. However, clinicians should be aware of this possible interaction. Anticholinergics The concurrent use of anticholinergics with oxycodone preparations may produce paralytic ileus. CNS Depressants Patients receiving narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics or other CNS depressants (including alcohol) concomitantly with oxycodone may exhibit an additive CNS depression. Interactive effects resulting in respiratory depression, hypotension, profound sedation, or coma may result if these drugs are taken in combination with the usual dosage of oxycodone. When such combined therapy is contemplated, the dose of one or both agents should be reduced. Mixed Agonist/Antagonist Opioid Analgesics Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) should be administered with caution to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone. In this situation, mixed agonist/antagonist analgesics may reduce the analgesic effect of oxycodone and/or may precipitate withdrawal symptoms in these patients. Monoamine Oxidase Inhibitors (MAOIs) MAOIs have been reported to intensify the effects of at least one opioid drug causing anxiety, confusion and significant depression of respiration or coma. The use of oxycodone is not recommended for patients taking MAOIs or within 14 days of stopping such treatment. Neuromuscular Blocking Agents Oxycodone, as well as other opioid analgesics, may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression. ACE-Inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking Combunox (oxycodone hcl and ibuprofen) concomitantly with ACE-inhibitors. Aspirin When Combunox (oxycodone hcl and ibuprofen) is administered with aspirin, its protein binding is reduced, although the clearance of free Combunox (oxycodone hcl and ibuprofen) is not altered. The clinical significance of this interaction is not known; however as with other products containing NSAIDs, concomitant administration of Combunox (oxycodone hcl and ibuprofen) and aspirin is not generally recommended because of the potential of increased adverse effects. Diuretics Ibuprofen has been shown to reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with Combunox (oxycodone hcl and ibuprofen) the patient should be observed closely for signs of renal failure (see WARNINGS; Renal Effects), as well as diuretic efficacy. Lithium Ibuprofen has been shown to produce an elevation of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%. These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID. Thus, when Combunox (oxycodone hcl and ibuprofen) and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity. Methotrexate Ibuprofen, as well as other NSAIDs, has been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This may indicate that ibuprofen could enhance the toxicity of methotrexate. Caution should be used when Combunox (oxycodone hcl and ibuprofen) is administered concomitantly with methotrexate. Warfarin The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a greater risk of serious GI bleeding than users of either drug alone.Read the Combunox Drug Interactions Center for a complete guide to possible interactions Learn More »

Source: http://www.rxlist.com

Carefully consider the potential benefits and risks of Combunox (oxycodone hcl and ibuprofen) and other treatment options before deciding to use Combunox (oxycodone hcl and ibuprofen) . Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS). Combunox (oxycodone hcl and ibuprofen) tablet is indicated for the short term (no more than 7 days) management of acute, moderate to severe pain.

Source: http://www.rxlist.com

Combunox (oxycodone hcl and ibuprofen) should not be administered to patients who have previously exhibited hypersensitivity to oxycodone HCl, ibuprofen, or any of Combunox (oxycodone hcl and ibuprofen) 's components. Combunox (oxycodone hcl and ibuprofen) should not be administered in any situation where opioids are contraindicated. This includes patients with significant respiratory depression (in unmonitored settings or the absence of resuscitative equipment) and patients with acute or severe bronchial asthma or hypercarbia. Patients known to be hypersensitive to other opioids may exhibit cross-sensitivity to oxycodone. Combunox (oxycodone hcl and ibuprofen) is contraindicated in any patient who has or is suspected of having paralytic ileus. Combunox (oxycodone hcl and ibuprofen) should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe anaphylactoid reactions to NSAIDs, some of which were fatal, have been reported in such patients (see WARNINGS; Anaphylactoid Reactions, and PRECAUTIONS; Pre-existing Asthma). Combunox (oxycodone hcl and ibuprofen) is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).Last reviewed on RxList: 9/23/2010
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

Following an acute overdosage, toxicity may result from oxycodone and/or ibuprofen. Signs and Symptoms Acute overdosage with oxycodone may be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, bradycardia, or hypotension. In severe cases death may occur. The toxicity of ibuprofen overdose is dependent on the amount of drug ingested and the time elapsed since ingestion, although individual response may vary, necessitating individual evaluation of each case. Although uncommon, serious toxicity and death have been reported in the medical literature with ibuprofen overdosage. The most frequently reported symptoms of ibuprofen overdose include abdominal pain, nausea, vomiting, lethargy, and drowsiness. Other central nervous system symptoms include headache, tinnitus, CNS depression, and seizures. Cardiovascular toxicity, including hypotension, bradycardia, tachycardia, and atrial fibrillation, have also been reported. Treatment In the treatment of opioid overdosage, primary attention should be given to the reestablishment of a patent airway and institution of assisted or controlled ventilation. Supportive measures (including oxygen and vasopressors) should be employed in the management of circulatory shock and pulmonary edema accompanying overdose, as indicated. Cardiac arrest or arrhythmias may require cardiac massage or defibrillation. The narcotic antagonist naloxone hydrochloride is a specific antidote against respiratory depression, which may result from overdosage or unusual sensitivity to narcotics including oxycodone. An appropriate dose of naloxone hydrochloride should be administered intravenously with simultaneous efforts at respiratory resuscitation. Since the duration of action of oxycodone may exceed that of the naloxone, the patient should be kept under continuous surveillance and repeated doses of the antagonist should be administered as needed to maintain adequate respiration. Management of hypotension, acidosis and gastrointestinal bleeding may be necessary. In cases of acute overdose, the stomach should be emptied through ipecac-induced emesis or gastric lavage. Orally administered activated charcoal may help in reducing the absorption and reabsorption of ibuprofen. Emesis is most effective if initiated within 30 minutes of ingestion. Induced emesis is not recommended in patients with impaired consciousness or overdoses greater than 400 mg/kg of the ibuprofen component in children because of the risk for convulsions and the potential for aspiration of gastric contents.

Source: http://www.rxlist.com

Combunox (oxycodone hcl and ibuprofen) are capsule shaped, white to off-white, film-coated tablets with “F” bisect “P” on one side and “5400” on the other side. Bottles of 100-NDC #0456-5200-01 Storage Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). Forest Pharmaceuticals, Inc. Subsidiary of Forest Laboratories, Inc. St. Louis, MO 63045 USA. Rev 2010. Last reviewed on RxList: 9/23/2010
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

General Combunox (oxycodone hcl and ibuprofen) cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids. The pharmacological activity of Combunox (oxycodone hcl and ibuprofen) in reducing fever and inflammation may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions. Special Risk Patients As with any opioid analgesic agent, Combunox (oxycodone hcl and ibuprofen) tablets should be used with caution in elderly or debilitated patients, and those with severe impairment of hepatic, pulmonary or renal function, hypothyroidism, Addison's disease, acute alcoholism, convulsive disorders, CNS depression or coma, delirium tremens, kyphoscoliosis associated with respiratory depression, toxic psychosis, prostatic hypertrophy or urethral stricture. The usual precautions should be observed and the possibility of respiratory depression, postural hypotension, and altered mental states should be kept in mind. Use in Pancreatic/Biliary Tract Disease Combunox (oxycodone hcl and ibuprofen) may cause spasm of the sphincter of Oddi and should be used with caution in patients with biliary tract disease, including acute pancreatitis. Opioids like Combunox (oxycodone hcl and ibuprofen) may cause increases in the serum amylase level. Cough Reflex Oxycodone suppresses the cough reflex; as with other opioid containing products, caution should be exercised when Combunox (oxycodone hcl and ibuprofen) is used postoperatively and in patients with pulmonary disease. Hepatic Effects Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs including ibuprofen as found in Combunox (oxycodone hcl and ibuprofen) . These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure, some of them with fatal outcomes have been reported. A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with Combunox (oxycodone hcl and ibuprofen) . If clinical signs and symptoms consistent with liver disease develop, or if systematic manifestations occur (e.g., eosinophilia, rash, etc.), Combunox (oxycodone hcl and ibuprofen) should be discontinued. Hematological Effects Anemia is sometimes seen in patients receiving NSAIDs, including ibuprofen as found in Combunox (oxycodone hcl and ibuprofen) . This may be due to fluid retention, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including ibuprofen, should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia. NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients receiving Combunox (oxycodone hcl and ibuprofen) who may be adversely affected by alterations in platelet function, such as those with coagulation disorders or patients receiving anticoagulants, should be carefully monitored. Patients previously treated with NSAIDs and currently using Combunox (oxycodone hcl and ibuprofen) should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia. Pre-existing Asthma Patients with asthma may have aspirin-sensitive asthma. The use of aspirin in patients with aspirin-sensitive asthma has been associated with severe bronchospasm, which can be fatal. Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, Combunox (oxycodone hcl and ibuprofen) should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with pre-existing asthma. Aseptic Meningitis Aseptic meningitis with fever and coma has been observed on rare occasions in patients on ibuprofen as found in COMBUNOX (oxycodone hcl and ibuprofen) . Although it is probably more likely to occur in patients with systemic lupus erythematosus and related connective tissue diseases, it has been reported in patients who do not have an underlying chronic disease. If signs or symptoms of meningitis develop in a patient on Combunox (oxycodone hcl and ibuprofen) , the possibility of its being related to ibuprofen should be considered. Information for Patients

1. Patients should be informed of the following information before initiating therapy with an NSAID and periodically during the course of ongoing therapy. Patients should also be encouraged to read the NSAID Medication Guide that accompanies each prescription dispensed.
2. Combunox (oxycodone hcl and ibuprofen) , similar to other opioid-containing analgesics, may impair mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery; patients should be cautioned accordingly.
3. The combination of this product with alcohol and other CNS depressants may produce an additive CNS depression and should be avoided.
4. Combunox (oxycodone hcl and ibuprofen) can be abused in a manner similar to other opioid agonists, legal or illicit. Patients should take the drug only for as long as it is prescribed, in the amounts prescribed, and no more frequently than prescribed.
5. Combunox (oxycodone hcl and ibuprofen) , like other NSAIDs, may cause serious CV side effects, such as MI or stroke, which may result in hospitalization and even death. Although serious CV events can occur without warning symptoms, patients should be alert for the signs and symptoms of chest pain, shortness of breath, weakness, slurring of speech, and should ask for medical advice when observing any indicative sign or symptoms. Patients should be apprised of the importance of this follow-up (see WARNINGS; Cardiovascular Effects).
6. Combunox (oxycodone hcl and ibuprofen) , like other NSAIDs, can cause GI discomfort and, rarely, serious GI side effects, such as ulcers and bleeding, which may result in hospitalization and even death. Although serious GI tract ulcerations and bleeding can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing any indicative sign or symptoms including epigastric pain, dyspepsia, melena, and hematemesis. Patients should be apprised of the importance of this follow-up (see WARNINGS; Gastrointestinal Effects - Risk of Ulceration, Bleeding, and Perforation).
7. Combunox (oxycodone hcl and ibuprofen) , like other NSAIDs, can cause serious skin side effects such as exfoliative dermatitis, SJS, and TEN, which may result in hospitalizations and even death. Although serious skin reactions may occur without warning, patients should be alert for the signs and symptoms of skin rash and blisters, fever or other signs of hypersensitivity, and should ask medical advice when observing any indicative signs or symptoms. Patients should be advised to stop the drug immediately if they develop any type of rash and contact their physician as soon as possible.
8. Patients should promptly report signs or symptoms of unexplained weight gain or edema to their physicians.
9. Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritius, jaundice, right upper quadrant tenderness, and “flu-like” symptoms). If these occur, patients should be instructed to seek immediate medical therapy.
10. Patients should be informed of the signs and symptoms of an anaphylactoid reaction (e.g. difficulty breathing, swelling of the face or throat). If these occur, patients should be instructed to seek immediate emergency help (see WARNINGS).
11. In late pregnancy, as with other NSAIDs, Combunox (oxycodone hcl and ibuprofen) should be avoided because it may cause premature closure of the ductus arteriosus.

Laboratory Tests Because serious GI tract ulcerations and bleeding can occur without warning symptoms, physicians should monitor for signs or symptoms of GI bleeding. Patients on long-term treatment with NSAIDs should have their CBC and a chemistry profile checked periodically. If clinical signs and symptoms consistent with liver or renal disease develop, systemic manifestations occur (e.g. eosinophilia, rash, etc.) or if abnormal liver tests persist or worsen, Combunox (oxycodone hcl and ibuprofen) should be discontinued. Carcinogenicity, Mutagenicity and Impairment of Fertility Studies to evaluate the potential effects of the combination of oxycodone and ibuprofen on carcinogenicity and mutagenicity have not been conducted. Oxycodone HCl was not genotoxic in the following assays: Ames bacterial mutuation assay, chromosomal aberrations in cultured human lymphocytes, and in vivo mouse micronucleus assay in mice. There was no evidence of impairment of fertility in either male or female Sprague-Dawley rats administered oxycodone HCl; ibuprofen up to (1:80 mg/kg/day) which is equivalent to 0.5-times the maximum recommended human daily dose (MRHD) (20:1600 mg/day) on a body surface area (mg/m² ) basis. Pregnancy Teratogenic Effects Pregnancy Category C prior to 30 weeks gestation; Category D starting at 30 weeks gestation Starting at 30 weeks gestation, Combunox (oxycodone hcl and ibuprofen) , and other NSAIDS, should be avoided by pregnant women as premature closure of the ductus arteriosus in the fetus may occur. Combunox (oxycodone hcl and ibuprofen) can cause fetal harm when administered to a pregnant woman starting at 30 weeks gestation. If Combunox (oxycodone hcl and ibuprofen) , and other NSAIDS, are used during this time period in pregnancy, the patient should be apprised of the potential hazard to a fetus. There are no adequate and well-controlled studies in pregnant women. Prior to 30 weeks gestation, Combunox (oxycodone hcl and ibuprofen) should be used during pregnancy only if the potential benefit justifies the risk to the fetus. Animal studies to assess the potential effects of the combination of oxycodone and ibuprofen on embryo-fetal development were conducted in the rat and rabbit model. Pregnant rats were treated by oral gavage with combination doses of oxycodone:ibuprofen mg/kg/day (0.25:20, 0.5:40, 1:80, or 2:160) on days 7-16 of gestation. There was no evidence for developmental toxicity or teratogenicity at any dose, although maternal toxicity was noted at doses of 0.5:40 and above. The highest dose tested in the rat (2:160 mg/kg/day) is equivalent to the maximum recommended human daily dose (20:1600 mg/day) on a body surface area (mg/m²) basis. This dose was associated with maternal toxicity (death, clinical signs, decreased BW). Pregnant rabbits were treated by oral gavage with combination doses of oxycodone/ibuprofen (0.38:30, 0.75:60, 1.5:120 or 3:240 mg/kg/day) on gestation days 7-19. Oxycodone/ibuprofen treatment was not teratogenic under the conditions of the assay. Maternal toxicity was noted at doses of 1.5:120 (reduced body weight and food consumption) and 3:240 mg/kg/day (mortality). The NOAEL for maternal toxicity, 0.75:60 mg/kg/day, is 0.75 fold the proposed maximum daily human dose based upon the body surface area. Developmental toxicity, as evidenced by delayed ossification and reduced fetal body weights, was noted at the highest dose, which is approximately 3 times the MRHD on a mg/m² basis, and is likely due to maternal toxicity. The fetal no adverse effect level (NOAEL) of 1.5:120 mg/kg/day is approximately 1.5 times the MRHD on a mg/m² basis. In a pre- and postnatal development study conducted in rats, there was increased mortality of pups born to dams dose with 0.5:40 mg/kg/day oxydocone:ibuprofen and above which is equivalent to 0.25-times of the MRHD (20:1600 mg/day) on a body surface area (mg/m²) basis. There was an increase in stillborn F1 pups and decrease in mean pup weight in dams dosed with 1:80 mg/kg/day oxycodone:ibuprofen, which is 0.5-times the MRHD (20:1600 mg/day) on a body surface area (mg/m²) basis. Non-teratogenic effects Babies born to mothers who have been taking opioids regularly prior to delivery will be physical dependent. The withdrawal signs include irritability and excessive crying, tremors, hyperactive reflexes, increased respiratory rate, increased stools, sneezing, yawning, vomiting, and fever. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose. There is no consensus on the best method of managing withdrawal. Labor and Delivery Combunox (oxycodone hcl and ibuprofen) should not be used during the third trimester of pregnancy due to the potential for ibuprofen to inhibit prostaglandin synthetase which may prolong pregnancy and inhibit labor. Oxycodone is not recommended for use in women during and immediately prior to labor and delivery because oral opioids may cause respiratory depression in the newborn. In rat studies with NSAIDs, as with other drugs known to inhibit prostaglandin synthesis, an increased incidence of dystocia, delayed parturition, and decreased pup survival occurred. The effects of Combunox (oxycodone hcl and ibuprofen) on labor and delivery in pregnant women are unknown. Nursing Mothers It is not known whether Combunox (oxycodone hcl and ibuprofen) is excreted in human milk. Oxycodone is excreted in human milk. Withdrawal symptoms and/or respiratory depression have been observed in neonates whose mothers were taking narcotic analgesics during pregnancy. Although adverse effects in the nursing infant have not been documented, withdrawal can occur in breast-feeding infants when maternal administration of an opioid analgesic is discontinued. Because many drugs are excreted in human-milk and because of the potential for serious adverse reactions in nursing infants from Combunox (oxycodone hcl and ibuprofen) , a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use In the placebo-controlled, clinical studies of pain following dental surgery, 109 patients between the ages of 14 and 17 years were administered a single dose of Combunox (oxycodone hcl and ibuprofen) . No apparent differences were noted in the safety of Combunox (oxycodone hcl and ibuprofen) in patients below and above 17 years of age. Combunox (oxycodone hcl and ibuprofen) has not been studied in patients under 14 years of age. Safety and effectiveness in pediatric patients below the age of 14 have not been established. Geriatric Use Of the total number of subjects in clinical studies of Combunox (oxycodone hcl and ibuprofen) , 89 patients were 65 and over, while 37 patients were 75 and over. No overall differences in safety were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. However, because the elderly may be more sensitive to the renal and gastrointestinal effects of nonsteroidal anti-inflammatory agents as well as possible increased risk of respiratory depression with opioids, extra caution should be used when treating the elderly with Combunox (oxycodone hcl and ibuprofen) .Last reviewed on RxList: 9/23/2010
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com